Ixazomib Citrate Proteasome Inhibitor Oncolytic
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F12%3A33141659" target="_blank" >RIV/61989592:15310/12:33141659 - isvavai.cz</a>
Result on the web
<a href="http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1835040&p_IsPs=N" target="_blank" >http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1835040&p_IsPs=N</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1358/dof.2012.37.8.1835040" target="_blank" >10.1358/dof.2012.37.8.1835040</a>
Alternative languages
Result language
angličtina
Original language name
Ixazomib Citrate Proteasome Inhibitor Oncolytic
Original language description
Ixazomib citrate, produced and patented by Millennium Pharmaceuticals, is one of the "new-generation" proteasome inhibitors following the success story of the first-in-class proteasome inhibitor bortezomib. Today, bortezomib is approved for multiple myeloma and mantle cell lymphoma, but has failed in clinical trials in patients with solid tumors. According to available preclinical data, ixazomib citrate may be more active in solid tumors. It also appears to be better tolerated by patients, as the most serious adverse event for bortezomib, neuropathy, has not yet been observed in clinical trials with ixazomib citrate. Ixazomib citrate can be administered both intravenously and orally.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/EE.2.3.20.0062" target="_blank" >EE.2.3.20.0062: An inexpensive drug Antabuse as anticancer remedy: mechanism of action and clinical trials</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Drugs of the Future
ISSN
0377-8282
e-ISSN
—
Volume of the periodical
37
Issue of the periodical within the volume
8
Country of publishing house
ES - SPAIN
Number of pages
5
Pages from-to
561-565
UT code for WoS article
000311192300003
EID of the result in the Scopus database
—